Form 4: Altimmune Director Klaus Schafer Granted 48,800 Stock Options

Altimmune, Inc. director Klaus Schafer was granted 48,800 stock options with an exercise price of $3.92, vesting over 12 months starting September 25, 2025.

Summary

• Director Klaus Schafer of Altimmune, Inc. was granted 48,800 stock options.
• The options have an exercise price of $3.92 per share.
• The grant date for the options is September 25, 2025.
• The options will vest in substantially equal monthly installments over 12 months, commencing September 25, 2025, subject to continued service.
• The expiration date for these options is September 25, 2035.
• The underlying security is Altimmune's Common Stock, par value $0.0001.
• Following this transaction, Klaus Schafer beneficially owns 48,800 derivative securities directly.
• A Power of Attorney was filed, authorizing Vipin K. Garg and Gregory Weaver to execute and file SEC forms on behalf of Klaus Schafer.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive signal of continued commitment and alignment of interests, a standard practice in corporate governance. It's not a major event but generally viewed favorably as an incentive.

Positives

• The grant of stock options aligns the director's interests with those of shareholders, incentivizing long-term company performance.
• The vesting schedule encourages continued service and commitment from the director over the next 12 months.

Negatives

• The issuance of new stock options could lead to potential future dilution for existing shareholders if exercised, although this is a standard compensation practice.

Risks

• The value of the stock options is contingent on Altimmune's stock price exceeding the $3.92 exercise price, posing a risk if the stock underperforms.
• The vesting is subject to the reporting person's continued service, meaning unvested options would be forfeited if service ceases.

Future Outlook

The stock options granted to Director Klaus Schafer will vest in substantially equal monthly installments over the 12 months following September 25, 2025, contingent on his continued service. This provides a future incentive structure for the director.

Industry Context

Granting stock options to directors is a common practice in the biotechnology and broader corporate sectors to attract and retain talent, align interests with shareholders, and incentivize long-term performance. The vesting schedule is also standard for such equity awards.

Comparison to Industry Standards

• The grant of 48,800 stock options with a 12-month vesting schedule and a 10-year expiration period is consistent with typical non-employee director compensation packages in the biotechnology industry for companies of similar market capitalization to Altimmune.
• While specific comparable companies are not named in the filing, such grants are standard practice for incentivizing board members.

Corporate Governance

Related Party Transactions

• The stock option grant to Director Klaus Schafer is a related party transaction, which is a standard form of compensation for board members.

Stakeholder Impact

• Shareholders: Potential future dilution if options are exercised, but also benefit from incentivized director performance.
• Management: The Power of Attorney streamlines administrative tasks for the director and the company's legal/compliance team.

Next Steps

• Klaus Schafer's continued service to Altimmune, Inc. for the next 12 months to fully vest the granted stock options.
• Potential exercise of vested stock options by Klaus Schafer at or above the $3.92 exercise price before the September 25, 2035 expiration date.

Key Dates

Recommendation

This filing reports a routine insider transaction (stock option grant) to a director as part of their compensation. While it aligns the director's interests with shareholders, it does not present new material information that would significantly alter the company's fundamental valuation or warrant a change in investment thesis. It is a standard governance item.

Keywords

Altimmune, ALT, Klaus Schafer, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Vesting Schedule, Biotechnology